Nanox Showcases End-to-End Medical Imaging Innovations and AI Solutions at ECR to Improve Patient Access and Outcomes

Nanox’s vision for global medical imaging development is transformational, a combination of hardware, software, and service delivery that applies unique design and AI-based advancements to expand care. At ECR in Vienna, March 4-8, 2026, the company will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time, as well as highlight AI solutions that support a preventive approach to health care.

“By leveraging our proprietary digital x-ray technology and AI-driven analytics…with a clinically driven approach…we aim to enhance the efficiency of routine imaging workflow and support early detection of diseases to improve patient outcomes,” says Erez Meltzer, CEO and Acting Chairman of Nanox.

ECR attendees will discuss, among other pressing issues, the importance of improving access while delivering imaging in an affordable fashion.

You’re still in the world of x-ray,
but it’s a much more capable3-D x-ray.
–Orit Wimpfheimer, MD, Chief Medical Officer of Nanox

The Nanox.ARC, combined with a portfolio of Nanox solutions, is intended to support diagnostic imaging across a range of clinical settings, with a focus on scalability and economic efficiency.

Advancing with Nanox.ARC

Nanox developed a unique digital tomosynthesis (DTS) system for use in diverse care settings, filling a niche between 2-D x-ray and CT to provide enhanced detail at a reasonable cost, lower radiation, and smaller footprint than CT. The Nanox.ARC, Conformité Européenne (CE) marked, is used across the whole-body for broad indications, delivering layered 3-D views with lower radiation than CT and providing improved clarity by reducing object superposition and minimizing pseudo-objects, says Orit Wimpfheimer, MD, Chief Medical Officer of Nanox.

The Nanox.ARC, a CE-marked and FDA-cleared multi-source digital tomosynthesis system, enables 3-D imaging at a lower cost and with less radiation than CT.

“[Our] super x-ray has particularly good use cases in both musculoskeletal and lung analysis, [including] much more detailed evaluation,” explains Dr. Wimpfheimer, noting that images are not obscured by objects like casts or metallic hardware. “Since you’re slicing coronal images…you get a detailed evaluation without having to resort to a CT scan. You're still in the world of x-ray, but it’s a much more capable 3-D x-ray.”

Of course, CT images come at a much higher cost, both in terms of expense and higher radiation exposure, Dr. Wimpfheimer adds, acknowledging the added complexities that CT often brings.

While DTS is not a new modality, the Nanox.ARC boasts a smaller footprint, remedying the challenges of bulkiness, inefficiency, and higher cost associated with previous tomosynthesis systems.

“In the Nanox.ARC, all x-ray tubes include our proprietary silicon-based, low-voltage, nanoscale cold cathode chip,” says Nogah Shabshin, MD, Medical Director of the ARC division at Nanox, explaining that the system configuration includes an arc-shaped array of tubes, acquiring projection data from multiple different angles. Further, “the table moves and the arc has a sweep, bringing us an additional 30 angles.”

The reconstructed data, presented in 30 to 100 thin-slice images, are viewed layer by layer in the coronal frame, which reduces obscuration common in overlapping anterior and posterior views. “This leads to a higher sensitivity and specificity,” explains Dr. Shabshin, potentially eliminating the need for CT for certain clinical use cases.

The Nanox.ARC delivers less radiation than CT, improving patient safety, and is simpler for the radiographer to operate, Dr. Shabshin adds, citing a “short learning curve” for both technologists and physicians, who enjoy quicker reads. With easy positioning and a plug-and-play setup, the DTS system is optimal in a variety of spaces.

Instead of referring patients off-site for advanced imaging, which can mean waiting days for results, the Nanox.ARC enables practices to perform high-resolution tomographic imaging at the point of care. The workflow benefits translate to reduced delays, minimal scheduling bottlenecks, accelerated clinical decision-making, and increased patient care access.

“Imagine an orthopedic, podiatry, chiropractic, or pulmonology clinic…that typically sends out for imaging or has very basic x-ray available,” suggests Dr. Wimpfheimer. These sites can now incorporate the Nanox.ARC into their workflow “due to its small footprint and easy-to-use set-up,” she says, noting that Nanox also offers teleradiology interpretations when additional support is needed. “They can obtain next-level imaging [in-house].”

Powering Preventive Care with AI

At ECR, Nanox will also highlight how AI-powered analysis tools assist clinicians in interpreting routine CT scans by highlighting early signs of chronic conditions. Using algorithms to identify risk indicators on existing scans, physicians are using the data to implement earlier care for cardiac disease, osteoporosis, and fatty liver disease.

“These diseases are much more expensive [to manage] down the road. If you find them earlier, you not only improve [the patient’s] quality of life, you decrease morbidity and mortality, and you decrease cost to the system,” Dr. Wimpfheimer says, noting that prevention requires “getting more out of every scan.”

Nanox AI is helping health systems do just that, identifying thousands of patients with conditions that were previously undetected.

At Michigan’s Corewell Health, Nanox’s AI cardiac solution identified 3,721 new at-risk patients in the first year, representing a 13-fold increase compared to the previous average annual reporting. In the UK ADOPT study, Nanox AI bone solution found up to 6 times more vertebral fractures than the national average from routine CT scans—more than 2,400 previously unknown patients with vertebral compression fractures.

“We're finding a lot more patients earlier in the disease processes…and we provide quantitative measurements of the findings, providing deep insights for clinicians to chart them into the appropriate clinical pathway,” says Dr. Wimpfheimer, adding that aortic valve calcification and body composition models are also in the works.

Potential Advancement in Lung Screening

DTS also shows promise as a potential alternative modality for lung cancer screening, where CT’s cost and infrastructure requirements can limit widespread implementation. Preliminary data from a Nanox.ARC study, to be presented at ECR by Dr. Shabshin on March 4 at 11:30 am CET, demonstrate the potential of DTS to stratify patients into low-risk and high-risk categories under Lung-RADS, with performance trends comparable to CT.

These early findings suggest that DTS may enable broader screening access in more care settings, at lower cost and reduced radiation exposure, further supporting Nanox’s mission to expand access to advanced medical imaging and AI-driven healthcare technologies, concludes Meltzer.

“Expanding access to these imaging capabilities aims to elevate the care for more patients and more communities, regardless of their geography or resources.”

Meet Nanox @ ECR 2026!